QuatRx Pharmaceuticals Presents Results from Ophena Phase 3 Study
ANN ARBOR, MI-QuatRx Pharmaceuticals today announced detailed primary endpoint results from a pivotal Phase 3 clinical trial of OphenaTM (ospemifene tablets) to treat postmenopausal women with symptoms of vulvovaginal atrophy, a common condition associated with menopause. The study successfully met all four co-primary endpoints. Women treated with OphenaTM at the 60 mg dose showed statistically [.. more ..]
Filed under: Health Care | No Comments »